Last updated: February 27, 2026
What is NDC 51079-0288?
The National Drug Code (NDC) 51079-0288 refers to MediChoice Ciprofloxacin Hydrochloride Injection, 200 mg/100 mL. This is an injectable antibiotic used to treat various bacterial infections.
Market Dynamics
Market Size and Demand
- Indications: Bacterial infections, including urinary tract, respiratory, skin, and intra-abdominal infections.
- Target Market: Hospitals, outpatient clinics, and infusion centers.
- Market Penetration: Limited to hospital settings; outpatient use is primarily via compounded formulations or alternate brands.
- Growth Drivers:
- Rising antimicrobial resistance leading to increased antibiotic use.
- Hospital admissions for severe bacterial infections.
- Key Competitors:
- Pfizer's Cipro (oral and injectable forms)
- Bayer's Cipro IV
- Generic manufacturers (e.g., Teva, Hikma)
Regulatory and Reimbursement Context
- FDA Status: Approved as a generic ciprofloxacin IV.
- Reimbursement Trends: Medicaid and Medicare reimburse hospitals based on formulary inclusion and negotiated prices.
- Pricing Regulation: Prices are influenced by generic competition and procurement contracts.
Market Challenges
- Increasing antibiotic stewardship programs reducing usage.
- Competition from other generic manufacturers.
- Protocols favoring oral over IV therapy when feasible.
Price Projections
Current Pricing Landscape
- Average Wholesale Price (AWP): Approximately $3.50 per 100 mL vial (varies by purchaser and region).
- Average Selling Price (ASP): Lower than AWP, typically around 20-30% discount.
- Hospital Acquisition Cost: Often 10-15% below ASP due to negotiated contracts.
Price Range
| Price Metric |
Estimated Range (per vial) |
Notes |
| Wholesale Acquisition Cost (WAC) |
$2.80 - $3.00 |
Used by hospital systems for procurement |
| Typical Sale Price |
$2.80 - $3.50 |
Includes negotiated discounts |
| Reimbursement Rate |
~$3.50 |
Based on Medicare/Medicaid rates |
Future Price Trends
- Prices are expected to remain stable due to ongoing generic competition.
- Slight declines may occur with increased production efficiencies or new entrants.
- Price increases are unlikely unless regulatory changes or shortages occur.
Influencing Factors
- Market share gains by specific manufacturers.
- Changes in hospital procurement policies.
- Patent or exclusivity status (not applicable; this version is a generic).
- Supply chain stability.
Strategic Insights
- Market Entry: Limited unless targeting niche applications or hospitals with specific formulary needs.
- Pricing Strategy: Focus on competitive bidding and cost containment to maintain or grow market share.
- Potential for Price Fluctuation: Driven by supply disruptions or policy shifts toward value-based care.
Key Takeaways
- The injectable ciprofloxacin market is mature with stable pricing driven by generic competition.
- Prices hover around $2.80 to $3.50 per 100 mL vial, with limited upward movement.
- Growth depends on hospital infection rates and stewardship policies; outright volume expansion may be constrained.
- Manufacturers should prioritize cost efficiency and formulary access to sustain margins.
FAQs
1. How does market demand for injectable ciprofloxacin compare to oral formulations?
Injectable forms are primarily reserved for severe infections in hospitalized patients, resulting in higher hospital-based demand but limited outpatient use.
2. Are there any upcoming patent protections or exclusivities for this drug?
No; as a generic, it has no patent protections. Market dynamics depend on generic competition and hospital procurement.
3. What factors could cause price increases in the future?
Supply shortages, regulatory changes, or hospital procurement shifts could increase prices temporarily.
4. How does the pricing of this generic compare globally?
Prices are generally lower in international markets due to different healthcare systems and regulatory policies.
5. What are the main risks for manufacturers in this market?
Market saturation, hospital budget constraints, and antimicrobial stewardship programs limit growth potential.
References
- IQVIA. (2022). Market Trends in Hospital Antibiotics.
- U.S. Food and Drug Administration. (2022). Approved Drug Products with Therapeutic Equivalence Evaluations.
- Medicare.gov. (2023). Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgery Center (ASC) Payment System.
- Medicaid Drug Rebate Program. (2022). Pricing and Reimbursement Policies.
- Generic Pharmaceutical Association. (2021). Market Competition and Price Trends in Generics.
